NIH Panel Releases New Statements on Tixagevimab Plus Cilgavimab and Anticoagulation in Hospitalized Patients with COVID-19

January 07, 2022

The COVID-19 Treatment Guidelines Panel (the Panel) has added 2 new statements to the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

The first statement provides the Panel’s recommendations for using tixagevimab plus cilgavimab (Evusheld) as PrEP in individuals who, if infected, are at high risk of progressing to severe COVID-19. It includes a list of moderately or severely immunocompromising conditions that will qualify an individual to receive this combination under the EUA. The statement also offers a detailed discussion of the clinical data that support the recommendations.

The second statement includes the Panel’s recommendations on the use of anticoagulation therapy in hospitalized, nonpregnant adults with COVID-19 who are receiving supplemental oxygen. These recommendations consider whether a patient is receiving intensive care. The statement includes additional recommendations on the use of anticoagulation therapy in pregnant adults with COVID-19 and discusses the clinical data that support the Panel’s recommendations.

For complete details, please see the full update on the COVID-19 Treatment Guidelines website.